IL-BAI
19.8.2019 19:52:08 CEST | Business Wire | Press release
BAI announced the finalists for the 2019 BAI Global Innovation Awards, the industry’s most prestigious awards program that celebrates transformative solutions in the financial services industry worldwide.
Now in its ninth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. Through hundreds of applications, the Innovation Circle , a panel of global financial services innovation leaders who thoroughly review each application, determined the top submissions.
The judges weigh each innovation on originality and impact on consumers and the industry. This year’s finalists showcase what leading financial services innovators in all regions of the world are doing to deliver new value to customers and employees, as well as improve efficiencies and profitability for their organizations.
The 2019 BAI Global Innovation Awards finalists are:
Best Application of Advanced Technology in a Product or Service
- Emirates NBD, Dubai, United Arab Emirates: Emirates NBD Blockchain Center of Excellence for Payments
- ISBANK, Istanbul, Turkey: AI Personal Assistant “Maxi”
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: FiMAX Trade Finance Blockchain Network
- Yapı Kredi, Istanbul, Turkey: Financial Document Corrective Analysis
Business Model Innovation
- CaixaBank S.A., Barcelona, Spain: Travel Marketplace
- DenizBank, Istanbul, Turkey: DenizBank Banking as a Platform Initiative
- KASIKORNBANK PCL, Bangkok, Thailand: K PLUS Loyalty Card Platform
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Ventures
Human Capital Innovation
- Alior Bank S.A., Warsaw, Poland: Smartphonisation
- DenizBank, Istanbul, Turkey: Crowdfunding Platform, Fonosentez
- HDFC Bank, Mumbai, India: Recruitment Hackathon
- ISBANK, Istanbul, Turkey: Isbank Agile Atelier
- Ping An Insurance, Shenzhen, China: AI Interview System
Innovation in Customer Experience
- CaixaBank S.A., Barcelona, Spain: ATM Facial Recognition
- Commonwealth Bank of Australia, Sydney, Australia: Customer Experience Transformation via AI
- Emirates NBD, Dubai, United Arab Emirates: Customer Experience Month
- FNB Insurance, Johannesburg, South Africa: Claims Excellence
- The Bank of East Asia, Limited, Hong Kong: i-Planner
Innovation in Marketing
- CaixaBank S.A., Barcelona, Spain: imaginBank Agile Digital Marketing Room
- Elevate Credit, Fort Worth, Texas, U.S.: Elevate Credit Campaign 2019
- Fifth Third Bancorp, Cincinnati, Ohio, U.S.: Momentum Campaign
- ISBANK, Istanbul, Turkey: Maximum Gaming Esports Platform
- Pelican State Credit Union, Baton Rouge, Louisiana, U.S.: Pelican State of Mind
Innovation in Societal and Community Impact
- Absa Group Limited, Johannesburg, South Africa: Kongola
- BMO Harris Bank and Springfour, Chicago, Illinois, U.S.: BMO Harris - SpringFour Partnership
- JUMO.WORLD, Cape Town, South Africa: JUMO.WORLD
- Union Bank of the Philippines, Pasig, Philippines: Project i2i
Innovative Accelerator or Incubator
- Alior Bank S.A., Warsaw, Poland: RBL_START
- Citi Ventures, D10X, San Francisco, California, U.S.: D10X
- ISBANK, Istanbul, Turkey: Workup Entrepreneurship Program
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Reach
- Woodforest National Bank, The Woodlands, Texas, U.S.: Woodforest Foundry
Innovative Touchpoints and Connected Experiences
- Aviva, Warsaw, Poland: Automated Claims Resolution Platform
- mBank S.A., Warsaw, Poland: Omni-channeling Asynchronous Chat
- Royal Bank of Canada (RBC), Toronto, Canada: DRIVE by RBC Ventures
Internal Process Innovation
- Alior Bank S.A., Warsaw, Poland: Smart Operations
- CommunityAmerica Financial Solutions, LLC, Lenexa, Kansas, U.S.: Dash360
- D10X, Citi, London, United Kingdom: Proxymity
- HDFC Bank, Mumbai, India: AI as a Service
- PKO Bank Polski, Warsaw, Poland: x-Platform
RegTech Innovation
- Hummingbird Regtech Inc, Walnut, California, U.S.: Regtech Solution
- Moody’s Analytics, San Francisco, California, U.S.: RiskFoundation™ Suite Hosted and Banking Cloud Solution
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: GAMMA Voiceprint Anti-fraud
- TSYS, Columbus, Georgia, U.S.: Foresight Score
- Yapı Kredi, Istanbul, Turkey: Digital Onboarding via Video Assistants
Congratulations to all the finalists of the BAI Global Innovation Awards. To learn more please visit BAIGlobalInnovations.com .
About BAI
As a nonprofit, independent organization, BAI delivers the financial services industry’s most actionable insights, enabling leaders to make smart business decisions every day. BAI is passionate about the trusted information and powerful tools that provide leaders with the clarity and confidence needed to drive positive change and move the financial services industry forward. For more information, visit www.bai.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom